Synopsis: These midcap companies across jewellery retail, renewable energy, e-commerce, and pharmaceuticals/biotechnology delivered exceptional Q2 performance, with net profit growth ranging from 100% to 870% and strong year-on-year sales expansion.
Midcap stocks are medium-sized companies with significant growth potential. Recently, several midcap firms across jewellery retail, renewable energy, e-commerce, and pharmaceuticals/biotechnology reported exceptional profit growth, with net profits rising sharply quarter-on-quarter, reflecting robust business expansion, strong demand, and efficient operations.
These companies often offer higher growth prospects than large-cap peers, making them attractive for investors seeking capital appreciation in sectors showing resilience and momentum.
Kalyan Jewellers India Ltd
Kalyan Jewellers is a leading Indian jewellery retailer founded in 1993 in Kerala. The company designs, manufactures, and sells gold, diamond, silver, and other studded jewellery across a wide range of price points. It has over 200 showrooms in India and an international presence in the Middle East.
With market capitalization of Rs. 51,137 cr, the shares of Kalyan Jewellers India Ltd are closed at Rs. 495.25 per share, from its previous close of Rs. 497.85 per share. Net profit of this stock jumped by 100% from Rs. 130 cr in Q2FY25 to Rs. 261 cr in Q2FY26. Sales are up by 30% to Rs. 7,856 cr from Rs. 6,065 cr over the same period.
Suzlon Energy Ltd
Suzlon Energy, founded in 1995 and headquartered in Pune, is a major Indian renewable energy company specializing in wind turbines. It has an installed wind energy capacity of over 20 GW across multiple countries. Suzlon provides end-to-end solutions, including equipment manufacturing, project development, and operations and maintenance..
With market capitalization of Rs. 78,940 cr, the shares of Suzlon Energy Ltd are closed at Rs. 57.58 per share, from its previous close of Rs. 57.56 per share. Net profit of this stock surged by 536% from Rs. 201 cr in Q2FY25 to Rs. 1,279 cr in Q2FY26. Sales are up by 84% to Rs. 3,871 cr from Rs. 2,103 cr over the same period.
FSN E‑Commerce Ventures Ltd
FSN E-Commerce Ventures, operating under the brand Nykaa, is an Indian digital retail company founded in 2012. It specializes in beauty, personal care, wellness, and fashion products. Nykaa operates through both an e-commerce platform and physical stores, offering an omnichannel experience.
With market capitalization of Rs. 74,458 cr, the shares of FSN E‑Commerce Ventures Ltd are closed at Rs. 260.20 per share, from its previous close of Rs. 256.95 per share. Net profit of this stock surged by 153% from Rs. 13 cr in Q2FY25 to Rs. 33 cr in Q2FY26. Sales are up by 25% to Rs. 2,346 cr from Rs. 1,875 cr over the same period.
Biocon Ltd
Biocon Ltd is a leading Indian biopharmaceutical company specializing in biologics, biosimilars, and novel biologics. It focuses on research, development, and manufacturing of therapies for diabetes, oncology, and autoimmune diseases, with a growing global presence and a strong emphasis on affordable healthcare solutions.
With market capitalization of Rs. 54,949 cr, the shares of Biocon Ltd are closed at Rs. 411 per share, from its previous close of Rs. 417.05 per share. Net profit of this stock surged by 391% from Rs. 27.1 cr in Q2FY25 to Rs. 133 cr in Q2FY26. Sales are up by 20% to Rs. 4,296 cr from Rs. 3,590 cr over the same period.
Laurus Labs Ltd
Laurus Labs, founded in 2005 and based in Hyderabad, is an Indian pharmaceutical and biotechnology company. It specializes in active pharmaceutical ingredients (APIs), generic formulations, custom development and manufacturing (CDMO), agro-chemicals, and biotechnology. The company has global regulatory certifications, multiple manufacturing sites, and is expanding its CDMO offerings along with its generics and API business.
With market capitalization of Rs. 53,866 cr, the shares of Laurus Labs Ltd are closed at Rs. 997.85 per share, from its previous close of Rs. 997.05 per share. Net profit of this stock increased by 870% from Rs. 20 cr in Q2FY25 to Rs. 194 cr in Q2FY26. Sales are up by 35% to Rs. 1,653 cr from Rs. 1,224 cr over the same period.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
